Global Oncolytic Virus CDMO Services Supply, Demand and Key Producers, 2023-2029
The global Oncolytic Virus CDMO Services market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Oncolytic virus CDMO service is a customized service provided to customers for the development and production of oncolytic virus vectors.
Oncolytic viruses (OVs) therapy is a new approach to treating tumors, which works by directly killing tumor cells and inducing the body's immune response. However, natural oncolytic viruses have certain limitations. Therefore, various viruses need to be used as vectors to enhance or weaken viral virulence through genetic modification and introduce new functional genes to improve their oncolytic effect. Currently, herpes simplex virus, adenovirus, vaccinia virus, vesicular stomatitis virus, measles virus, mumps virus, polio virus, etc. can be used as oncolytic virus vectors. These viral vectors can target and kill different tumor cells through different genetic modification methods, achieving better oncolytic effects.
Oncolytic virus CDMO services can accelerate the R&D and production process of oncolytic viruses, provide customers with high-quality oncolytic virus products, and promote innovation in the field of tumor treatment.
This report studies the global Oncolytic Virus CDMO Services demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oncolytic Virus CDMO Services, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oncolytic Virus CDMO Services that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oncolytic Virus CDMO Services total market, 2018-2029, (USD Million)
Global Oncolytic Virus CDMO Services total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Oncolytic Virus CDMO Services total market, key domestic companies and share, (USD Million)
Global Oncolytic Virus CDMO Services revenue by player and market share 2018-2023, (USD Million)
Global Oncolytic Virus CDMO Services total market by Type, CAGR, 2018-2029, (USD Million)
Global Oncolytic Virus CDMO Services total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Oncolytic Virus CDMO Services market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech and ABL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oncolytic Virus CDMO Services market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Oncolytic Virus CDMO Services Market, By Region:
1. How big is the global Oncolytic Virus CDMO Services market?
2. What is the demand of the global Oncolytic Virus CDMO Services market?
3. What is the year over year growth of the global Oncolytic Virus CDMO Services market?
4. What is the total value of the global Oncolytic Virus CDMO Services market?
5. Who are the major players in the global Oncolytic Virus CDMO Services market?
Oncolytic virus CDMO service is a customized service provided to customers for the development and production of oncolytic virus vectors.
Oncolytic viruses (OVs) therapy is a new approach to treating tumors, which works by directly killing tumor cells and inducing the body's immune response. However, natural oncolytic viruses have certain limitations. Therefore, various viruses need to be used as vectors to enhance or weaken viral virulence through genetic modification and introduce new functional genes to improve their oncolytic effect. Currently, herpes simplex virus, adenovirus, vaccinia virus, vesicular stomatitis virus, measles virus, mumps virus, polio virus, etc. can be used as oncolytic virus vectors. These viral vectors can target and kill different tumor cells through different genetic modification methods, achieving better oncolytic effects.
Oncolytic virus CDMO services can accelerate the R&D and production process of oncolytic viruses, provide customers with high-quality oncolytic virus products, and promote innovation in the field of tumor treatment.
This report studies the global Oncolytic Virus CDMO Services demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oncolytic Virus CDMO Services, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oncolytic Virus CDMO Services that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oncolytic Virus CDMO Services total market, 2018-2029, (USD Million)
Global Oncolytic Virus CDMO Services total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Oncolytic Virus CDMO Services total market, key domestic companies and share, (USD Million)
Global Oncolytic Virus CDMO Services revenue by player and market share 2018-2023, (USD Million)
Global Oncolytic Virus CDMO Services total market by Type, CAGR, 2018-2029, (USD Million)
Global Oncolytic Virus CDMO Services total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Oncolytic Virus CDMO Services market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm (Vibalogics), IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza, Creative Biolabs, Takara Bio, Libentech and ABL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oncolytic Virus CDMO Services market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Oncolytic Virus CDMO Services Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Oncolytic Herpes Simplex Virus
- Oncolytic Adenovirus
- Oncolytic Vaccinia Virus
- Others
- R&D
- Biopharmaceutical Manufacturers
- Others
- Recipharm (Vibalogics)
- IDT Biologika
- FUJIFILM Diosynth Biotechnologies
- Exothera
- Lonza
- Creative Biolabs
- Takara Bio
- Libentech
- ABL
- Nabios
- Halix
- Obio Technology
- Porton Advanced
- WuXi ATU
- Genevoyager
1. How big is the global Oncolytic Virus CDMO Services market?
2. What is the demand of the global Oncolytic Virus CDMO Services market?
3. What is the year over year growth of the global Oncolytic Virus CDMO Services market?
4. What is the total value of the global Oncolytic Virus CDMO Services market?
5. Who are the major players in the global Oncolytic Virus CDMO Services market?
1 SUPPLY SUMMARY
1.1 Oncolytic Virus CDMO Services Introduction
1.2 World Oncolytic Virus CDMO Services Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Oncolytic Virus CDMO Services Total Market by Region (by Headquarter Location)
1.3.1 World Oncolytic Virus CDMO Services Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.3 China Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.4 Europe Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.5 Japan Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.6 South Korea Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.7 ASEAN Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.8 India Oncolytic Virus CDMO Services Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oncolytic Virus CDMO Services Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oncolytic Virus CDMO Services Major Market Trends
2 DEMAND SUMMARY
2.1 World Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.2 World Oncolytic Virus CDMO Services Consumption Value by Region
2.2.1 World Oncolytic Virus CDMO Services Consumption Value by Region (2018-2023)
2.2.2 World Oncolytic Virus CDMO Services Consumption Value Forecast by Region (2024-2029)
2.3 United States Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.4 China Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.5 Europe Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.6 Japan Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.7 South Korea Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.8 ASEAN Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.9 India Oncolytic Virus CDMO Services Consumption Value (2018-2029)
3 WORLD ONCOLYTIC VIRUS CDMO SERVICES COMPANIES COMPETITIVE ANALYSIS
3.1 World Oncolytic Virus CDMO Services Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oncolytic Virus CDMO Services Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oncolytic Virus CDMO Services in 2022
3.2.3 Global Concentration Ratios (CR8) for Oncolytic Virus CDMO Services in 2022
3.3 Oncolytic Virus CDMO Services Company Evaluation Quadrant
3.4 Oncolytic Virus CDMO Services Market: Overall Company Footprint Analysis
3.4.1 Oncolytic Virus CDMO Services Market: Region Footprint
3.4.2 Oncolytic Virus CDMO Services Market: Company Product Type Footprint
3.4.3 Oncolytic Virus CDMO Services Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oncolytic Virus CDMO Services Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oncolytic Virus CDMO Services Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Oncolytic Virus CDMO Services Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Oncolytic Virus CDMO Services Consumption Value Comparison
4.2.1 United States VS China: Oncolytic Virus CDMO Services Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Oncolytic Virus CDMO Services Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Oncolytic Virus CDMO Services Companies and Market Share, 2018-2023
4.3.1 United States Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023)
4.4 China Based Companies Oncolytic Virus CDMO Services Revenue and Market Share, 2018-2023
4.4.1 China Based Oncolytic Virus CDMO Services Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023)
4.5 Rest of World Based Oncolytic Virus CDMO Services Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Oncolytic Virus CDMO Services Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Oncolytic Herpes Simplex Virus
5.2.2 Oncolytic Adenovirus
5.2.3 Oncolytic Vaccinia Virus
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Oncolytic Virus CDMO Services Market Size by Type (2018-2023)
5.3.2 World Oncolytic Virus CDMO Services Market Size by Type (2024-2029)
5.3.3 World Oncolytic Virus CDMO Services Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Oncolytic Virus CDMO Services Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 R&D
6.2.2 Biopharmaceutical Manufacturers
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Oncolytic Virus CDMO Services Market Size by Application (2018-2023)
6.3.2 World Oncolytic Virus CDMO Services Market Size by Application (2024-2029)
6.3.3 World Oncolytic Virus CDMO Services Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Recipharm (Vibalogics)
7.1.1 Recipharm (Vibalogics) Details
7.1.2 Recipharm (Vibalogics) Major Business
7.1.3 Recipharm (Vibalogics) Oncolytic Virus CDMO Services Product and Services
7.1.4 Recipharm (Vibalogics) Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Recipharm (Vibalogics) Recent Developments/Updates
7.1.6 Recipharm (Vibalogics) Competitive Strengths & Weaknesses
7.2 IDT Biologika
7.2.1 IDT Biologika Details
7.2.2 IDT Biologika Major Business
7.2.3 IDT Biologika Oncolytic Virus CDMO Services Product and Services
7.2.4 IDT Biologika Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 IDT Biologika Recent Developments/Updates
7.2.6 IDT Biologika Competitive Strengths & Weaknesses
7.3 FUJIFILM Diosynth Biotechnologies
7.3.1 FUJIFILM Diosynth Biotechnologies Details
7.3.2 FUJIFILM Diosynth Biotechnologies Major Business
7.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Product and Services
7.3.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
7.3.6 FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
7.4 Exothera
7.4.1 Exothera Details
7.4.2 Exothera Major Business
7.4.3 Exothera Oncolytic Virus CDMO Services Product and Services
7.4.4 Exothera Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Exothera Recent Developments/Updates
7.4.6 Exothera Competitive Strengths & Weaknesses
7.5 Lonza
7.5.1 Lonza Details
7.5.2 Lonza Major Business
7.5.3 Lonza Oncolytic Virus CDMO Services Product and Services
7.5.4 Lonza Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Lonza Recent Developments/Updates
7.5.6 Lonza Competitive Strengths & Weaknesses
7.6 Creative Biolabs
7.6.1 Creative Biolabs Details
7.6.2 Creative Biolabs Major Business
7.6.3 Creative Biolabs Oncolytic Virus CDMO Services Product and Services
7.6.4 Creative Biolabs Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Creative Biolabs Recent Developments/Updates
7.6.6 Creative Biolabs Competitive Strengths & Weaknesses
7.7 Takara Bio
7.7.1 Takara Bio Details
7.7.2 Takara Bio Major Business
7.7.3 Takara Bio Oncolytic Virus CDMO Services Product and Services
7.7.4 Takara Bio Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Takara Bio Recent Developments/Updates
7.7.6 Takara Bio Competitive Strengths & Weaknesses
7.8 Libentech
7.8.1 Libentech Details
7.8.2 Libentech Major Business
7.8.3 Libentech Oncolytic Virus CDMO Services Product and Services
7.8.4 Libentech Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Libentech Recent Developments/Updates
7.8.6 Libentech Competitive Strengths & Weaknesses
7.9 ABL
7.9.1 ABL Details
7.9.2 ABL Major Business
7.9.3 ABL Oncolytic Virus CDMO Services Product and Services
7.9.4 ABL Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 ABL Recent Developments/Updates
7.9.6 ABL Competitive Strengths & Weaknesses
7.10 Nabios
7.10.1 Nabios Details
7.10.2 Nabios Major Business
7.10.3 Nabios Oncolytic Virus CDMO Services Product and Services
7.10.4 Nabios Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Nabios Recent Developments/Updates
7.10.6 Nabios Competitive Strengths & Weaknesses
7.11 Halix
7.11.1 Halix Details
7.11.2 Halix Major Business
7.11.3 Halix Oncolytic Virus CDMO Services Product and Services
7.11.4 Halix Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Halix Recent Developments/Updates
7.11.6 Halix Competitive Strengths & Weaknesses
7.12 Obio Technology
7.12.1 Obio Technology Details
7.12.2 Obio Technology Major Business
7.12.3 Obio Technology Oncolytic Virus CDMO Services Product and Services
7.12.4 Obio Technology Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Obio Technology Recent Developments/Updates
7.12.6 Obio Technology Competitive Strengths & Weaknesses
7.13 Porton Advanced
7.13.1 Porton Advanced Details
7.13.2 Porton Advanced Major Business
7.13.3 Porton Advanced Oncolytic Virus CDMO Services Product and Services
7.13.4 Porton Advanced Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Porton Advanced Recent Developments/Updates
7.13.6 Porton Advanced Competitive Strengths & Weaknesses
7.14 WuXi ATU
7.14.1 WuXi ATU Details
7.14.2 WuXi ATU Major Business
7.14.3 WuXi ATU Oncolytic Virus CDMO Services Product and Services
7.14.4 WuXi ATU Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 WuXi ATU Recent Developments/Updates
7.14.6 WuXi ATU Competitive Strengths & Weaknesses
7.15 Genevoyager
7.15.1 Genevoyager Details
7.15.2 Genevoyager Major Business
7.15.3 Genevoyager Oncolytic Virus CDMO Services Product and Services
7.15.4 Genevoyager Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Genevoyager Recent Developments/Updates
7.15.6 Genevoyager Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Oncolytic Virus CDMO Services Industry Chain
8.2 Oncolytic Virus CDMO Services Upstream Analysis
8.3 Oncolytic Virus CDMO Services Midstream Analysis
8.4 Oncolytic Virus CDMO Services Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Oncolytic Virus CDMO Services Introduction
1.2 World Oncolytic Virus CDMO Services Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Oncolytic Virus CDMO Services Total Market by Region (by Headquarter Location)
1.3.1 World Oncolytic Virus CDMO Services Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.3 China Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.4 Europe Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.5 Japan Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.6 South Korea Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.7 ASEAN Oncolytic Virus CDMO Services Market Size (2018-2029)
1.3.8 India Oncolytic Virus CDMO Services Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oncolytic Virus CDMO Services Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oncolytic Virus CDMO Services Major Market Trends
2 DEMAND SUMMARY
2.1 World Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.2 World Oncolytic Virus CDMO Services Consumption Value by Region
2.2.1 World Oncolytic Virus CDMO Services Consumption Value by Region (2018-2023)
2.2.2 World Oncolytic Virus CDMO Services Consumption Value Forecast by Region (2024-2029)
2.3 United States Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.4 China Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.5 Europe Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.6 Japan Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.7 South Korea Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.8 ASEAN Oncolytic Virus CDMO Services Consumption Value (2018-2029)
2.9 India Oncolytic Virus CDMO Services Consumption Value (2018-2029)
3 WORLD ONCOLYTIC VIRUS CDMO SERVICES COMPANIES COMPETITIVE ANALYSIS
3.1 World Oncolytic Virus CDMO Services Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oncolytic Virus CDMO Services Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oncolytic Virus CDMO Services in 2022
3.2.3 Global Concentration Ratios (CR8) for Oncolytic Virus CDMO Services in 2022
3.3 Oncolytic Virus CDMO Services Company Evaluation Quadrant
3.4 Oncolytic Virus CDMO Services Market: Overall Company Footprint Analysis
3.4.1 Oncolytic Virus CDMO Services Market: Region Footprint
3.4.2 Oncolytic Virus CDMO Services Market: Company Product Type Footprint
3.4.3 Oncolytic Virus CDMO Services Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oncolytic Virus CDMO Services Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oncolytic Virus CDMO Services Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Oncolytic Virus CDMO Services Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Oncolytic Virus CDMO Services Consumption Value Comparison
4.2.1 United States VS China: Oncolytic Virus CDMO Services Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Oncolytic Virus CDMO Services Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Oncolytic Virus CDMO Services Companies and Market Share, 2018-2023
4.3.1 United States Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023)
4.4 China Based Companies Oncolytic Virus CDMO Services Revenue and Market Share, 2018-2023
4.4.1 China Based Oncolytic Virus CDMO Services Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023)
4.5 Rest of World Based Oncolytic Virus CDMO Services Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Oncolytic Virus CDMO Services Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Oncolytic Herpes Simplex Virus
5.2.2 Oncolytic Adenovirus
5.2.3 Oncolytic Vaccinia Virus
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Oncolytic Virus CDMO Services Market Size by Type (2018-2023)
5.3.2 World Oncolytic Virus CDMO Services Market Size by Type (2024-2029)
5.3.3 World Oncolytic Virus CDMO Services Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Oncolytic Virus CDMO Services Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 R&D
6.2.2 Biopharmaceutical Manufacturers
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Oncolytic Virus CDMO Services Market Size by Application (2018-2023)
6.3.2 World Oncolytic Virus CDMO Services Market Size by Application (2024-2029)
6.3.3 World Oncolytic Virus CDMO Services Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Recipharm (Vibalogics)
7.1.1 Recipharm (Vibalogics) Details
7.1.2 Recipharm (Vibalogics) Major Business
7.1.3 Recipharm (Vibalogics) Oncolytic Virus CDMO Services Product and Services
7.1.4 Recipharm (Vibalogics) Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Recipharm (Vibalogics) Recent Developments/Updates
7.1.6 Recipharm (Vibalogics) Competitive Strengths & Weaknesses
7.2 IDT Biologika
7.2.1 IDT Biologika Details
7.2.2 IDT Biologika Major Business
7.2.3 IDT Biologika Oncolytic Virus CDMO Services Product and Services
7.2.4 IDT Biologika Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 IDT Biologika Recent Developments/Updates
7.2.6 IDT Biologika Competitive Strengths & Weaknesses
7.3 FUJIFILM Diosynth Biotechnologies
7.3.1 FUJIFILM Diosynth Biotechnologies Details
7.3.2 FUJIFILM Diosynth Biotechnologies Major Business
7.3.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Product and Services
7.3.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
7.3.6 FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
7.4 Exothera
7.4.1 Exothera Details
7.4.2 Exothera Major Business
7.4.3 Exothera Oncolytic Virus CDMO Services Product and Services
7.4.4 Exothera Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Exothera Recent Developments/Updates
7.4.6 Exothera Competitive Strengths & Weaknesses
7.5 Lonza
7.5.1 Lonza Details
7.5.2 Lonza Major Business
7.5.3 Lonza Oncolytic Virus CDMO Services Product and Services
7.5.4 Lonza Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Lonza Recent Developments/Updates
7.5.6 Lonza Competitive Strengths & Weaknesses
7.6 Creative Biolabs
7.6.1 Creative Biolabs Details
7.6.2 Creative Biolabs Major Business
7.6.3 Creative Biolabs Oncolytic Virus CDMO Services Product and Services
7.6.4 Creative Biolabs Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Creative Biolabs Recent Developments/Updates
7.6.6 Creative Biolabs Competitive Strengths & Weaknesses
7.7 Takara Bio
7.7.1 Takara Bio Details
7.7.2 Takara Bio Major Business
7.7.3 Takara Bio Oncolytic Virus CDMO Services Product and Services
7.7.4 Takara Bio Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Takara Bio Recent Developments/Updates
7.7.6 Takara Bio Competitive Strengths & Weaknesses
7.8 Libentech
7.8.1 Libentech Details
7.8.2 Libentech Major Business
7.8.3 Libentech Oncolytic Virus CDMO Services Product and Services
7.8.4 Libentech Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Libentech Recent Developments/Updates
7.8.6 Libentech Competitive Strengths & Weaknesses
7.9 ABL
7.9.1 ABL Details
7.9.2 ABL Major Business
7.9.3 ABL Oncolytic Virus CDMO Services Product and Services
7.9.4 ABL Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 ABL Recent Developments/Updates
7.9.6 ABL Competitive Strengths & Weaknesses
7.10 Nabios
7.10.1 Nabios Details
7.10.2 Nabios Major Business
7.10.3 Nabios Oncolytic Virus CDMO Services Product and Services
7.10.4 Nabios Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Nabios Recent Developments/Updates
7.10.6 Nabios Competitive Strengths & Weaknesses
7.11 Halix
7.11.1 Halix Details
7.11.2 Halix Major Business
7.11.3 Halix Oncolytic Virus CDMO Services Product and Services
7.11.4 Halix Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Halix Recent Developments/Updates
7.11.6 Halix Competitive Strengths & Weaknesses
7.12 Obio Technology
7.12.1 Obio Technology Details
7.12.2 Obio Technology Major Business
7.12.3 Obio Technology Oncolytic Virus CDMO Services Product and Services
7.12.4 Obio Technology Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Obio Technology Recent Developments/Updates
7.12.6 Obio Technology Competitive Strengths & Weaknesses
7.13 Porton Advanced
7.13.1 Porton Advanced Details
7.13.2 Porton Advanced Major Business
7.13.3 Porton Advanced Oncolytic Virus CDMO Services Product and Services
7.13.4 Porton Advanced Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Porton Advanced Recent Developments/Updates
7.13.6 Porton Advanced Competitive Strengths & Weaknesses
7.14 WuXi ATU
7.14.1 WuXi ATU Details
7.14.2 WuXi ATU Major Business
7.14.3 WuXi ATU Oncolytic Virus CDMO Services Product and Services
7.14.4 WuXi ATU Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 WuXi ATU Recent Developments/Updates
7.14.6 WuXi ATU Competitive Strengths & Weaknesses
7.15 Genevoyager
7.15.1 Genevoyager Details
7.15.2 Genevoyager Major Business
7.15.3 Genevoyager Oncolytic Virus CDMO Services Product and Services
7.15.4 Genevoyager Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Genevoyager Recent Developments/Updates
7.15.6 Genevoyager Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Oncolytic Virus CDMO Services Industry Chain
8.2 Oncolytic Virus CDMO Services Upstream Analysis
8.3 Oncolytic Virus CDMO Services Midstream Analysis
8.4 Oncolytic Virus CDMO Services Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Oncolytic Virus CDMO Services Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Oncolytic Virus CDMO Services Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Oncolytic Virus CDMO Services Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oncolytic Virus CDMO Services Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Oncolytic Virus CDMO Services Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Oncolytic Virus CDMO Services Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Oncolytic Virus CDMO Services Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Oncolytic Virus CDMO Services Players in 2022
Table 12. World Oncolytic Virus CDMO Services Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Oncolytic Virus CDMO Services Company Evaluation Quadrant
Table 14. Head Office of Key Oncolytic Virus CDMO Services Player
Table 15. Oncolytic Virus CDMO Services Market: Company Product Type Footprint
Table 16. Oncolytic Virus CDMO Services Market: Company Product Application Footprint
Table 17. Oncolytic Virus CDMO Services Mergers & Acquisitions Activity
Table 18. United States VS China Oncolytic Virus CDMO Services Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Oncolytic Virus CDMO Services Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Oncolytic Virus CDMO Services Revenue Market Share (2018-2023)
Table 23. China Based Oncolytic Virus CDMO Services Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Oncolytic Virus CDMO Services Revenue Market Share (2018-2023)
Table 26. Rest of World Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Oncolytic Virus CDMO Services Revenue Market Share (2018-2023)
Table 29. World Oncolytic Virus CDMO Services Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Oncolytic Virus CDMO Services Market Size by Type (2018-2023) & (USD Million)
Table 31. World Oncolytic Virus CDMO Services Market Size by Type (2024-2029) & (USD Million)
Table 32. World Oncolytic Virus CDMO Services Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Oncolytic Virus CDMO Services Market Size by Application (2018-2023) & (USD Million)
Table 34. World Oncolytic Virus CDMO Services Market Size by Application (2024-2029) & (USD Million)
Table 35. Recipharm (Vibalogics) Basic Information, Area Served and Competitors
Table 36. Recipharm (Vibalogics) Major Business
Table 37. Recipharm (Vibalogics) Oncolytic Virus CDMO Services Product and Services
Table 38. Recipharm (Vibalogics) Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Recipharm (Vibalogics) Recent Developments/Updates
Table 40. Recipharm (Vibalogics) Competitive Strengths & Weaknesses
Table 41. IDT Biologika Basic Information, Area Served and Competitors
Table 42. IDT Biologika Major Business
Table 43. IDT Biologika Oncolytic Virus CDMO Services Product and Services
Table 44. IDT Biologika Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. IDT Biologika Recent Developments/Updates
Table 46. IDT Biologika Competitive Strengths & Weaknesses
Table 47. FUJIFILM Diosynth Biotechnologies Basic Information, Area Served and Competitors
Table 48. FUJIFILM Diosynth Biotechnologies Major Business
Table 49. FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Product and Services
Table 50. FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
Table 52. FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
Table 53. Exothera Basic Information, Area Served and Competitors
Table 54. Exothera Major Business
Table 55. Exothera Oncolytic Virus CDMO Services Product and Services
Table 56. Exothera Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Exothera Recent Developments/Updates
Table 58. Exothera Competitive Strengths & Weaknesses
Table 59. Lonza Basic Information, Area Served and Competitors
Table 60. Lonza Major Business
Table 61. Lonza Oncolytic Virus CDMO Services Product and Services
Table 62. Lonza Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Lonza Recent Developments/Updates
Table 64. Lonza Competitive Strengths & Weaknesses
Table 65. Creative Biolabs Basic Information, Area Served and Competitors
Table 66. Creative Biolabs Major Business
Table 67. Creative Biolabs Oncolytic Virus CDMO Services Product and Services
Table 68. Creative Biolabs Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Creative Biolabs Recent Developments/Updates
Table 70. Creative Biolabs Competitive Strengths & Weaknesses
Table 71. Takara Bio Basic Information, Area Served and Competitors
Table 72. Takara Bio Major Business
Table 73. Takara Bio Oncolytic Virus CDMO Services Product and Services
Table 74. Takara Bio Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Takara Bio Recent Developments/Updates
Table 76. Takara Bio Competitive Strengths & Weaknesses
Table 77. Libentech Basic Information, Area Served and Competitors
Table 78. Libentech Major Business
Table 79. Libentech Oncolytic Virus CDMO Services Product and Services
Table 80. Libentech Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Libentech Recent Developments/Updates
Table 82. Libentech Competitive Strengths & Weaknesses
Table 83. ABL Basic Information, Area Served and Competitors
Table 84. ABL Major Business
Table 85. ABL Oncolytic Virus CDMO Services Product and Services
Table 86. ABL Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. ABL Recent Developments/Updates
Table 88. ABL Competitive Strengths & Weaknesses
Table 89. Nabios Basic Information, Area Served and Competitors
Table 90. Nabios Major Business
Table 91. Nabios Oncolytic Virus CDMO Services Product and Services
Table 92. Nabios Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Nabios Recent Developments/Updates
Table 94. Nabios Competitive Strengths & Weaknesses
Table 95. Halix Basic Information, Area Served and Competitors
Table 96. Halix Major Business
Table 97. Halix Oncolytic Virus CDMO Services Product and Services
Table 98. Halix Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Halix Recent Developments/Updates
Table 100. Halix Competitive Strengths & Weaknesses
Table 101. Obio Technology Basic Information, Area Served and Competitors
Table 102. Obio Technology Major Business
Table 103. Obio Technology Oncolytic Virus CDMO Services Product and Services
Table 104. Obio Technology Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Obio Technology Recent Developments/Updates
Table 106. Obio Technology Competitive Strengths & Weaknesses
Table 107. Porton Advanced Basic Information, Area Served and Competitors
Table 108. Porton Advanced Major Business
Table 109. Porton Advanced Oncolytic Virus CDMO Services Product and Services
Table 110. Porton Advanced Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Porton Advanced Recent Developments/Updates
Table 112. Porton Advanced Competitive Strengths & Weaknesses
Table 113. WuXi ATU Basic Information, Area Served and Competitors
Table 114. WuXi ATU Major Business
Table 115. WuXi ATU Oncolytic Virus CDMO Services Product and Services
Table 116. WuXi ATU Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. WuXi ATU Recent Developments/Updates
Table 118. Genevoyager Basic Information, Area Served and Competitors
Table 119. Genevoyager Major Business
Table 120. Genevoyager Oncolytic Virus CDMO Services Product and Services
Table 121. Genevoyager Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Oncolytic Virus CDMO Services Upstream (Raw Materials)
Table 123. Oncolytic Virus CDMO Services Typical Customers
LIST OF FIGURE
Figure 1. Oncolytic Virus CDMO Services Picture
Figure 2. World Oncolytic Virus CDMO Services Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Oncolytic Virus CDMO Services Total Market Size (2018-2029) & (USD Million)
Figure 4. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 13. Oncolytic Virus CDMO Services Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 16. World Oncolytic Virus CDMO Services Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 18. China Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 23. India Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Oncolytic Virus CDMO Services by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oncolytic Virus CDMO Services Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oncolytic Virus CDMO Services Markets in 2022
Figure 27. United States VS China: Oncolytic Virus CDMO Services Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Oncolytic Virus CDMO Services Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Oncolytic Virus CDMO Services Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Oncolytic Virus CDMO Services Market Size Market Share by Type in 2022
Figure 31. Oncolytic Herpes Simplex Virus
Figure 32. Oncolytic Adenovirus
Figure 33. Oncolytic Vaccinia Virus
Figure 34. Others
Figure 35. World Oncolytic Virus CDMO Services Market Size Market Share by Type (2018-2029)
Figure 36. World Oncolytic Virus CDMO Services Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Oncolytic Virus CDMO Services Market Size Market Share by Application in 2022
Figure 38. R&D
Figure 39. Biopharmaceutical Manufacturers
Figure 40. Others
Figure 41. Oncolytic Virus CDMO Services Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
Table 1. World Oncolytic Virus CDMO Services Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Oncolytic Virus CDMO Services Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Oncolytic Virus CDMO Services Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oncolytic Virus CDMO Services Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Oncolytic Virus CDMO Services Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Oncolytic Virus CDMO Services Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Oncolytic Virus CDMO Services Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Oncolytic Virus CDMO Services Players in 2022
Table 12. World Oncolytic Virus CDMO Services Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Oncolytic Virus CDMO Services Company Evaluation Quadrant
Table 14. Head Office of Key Oncolytic Virus CDMO Services Player
Table 15. Oncolytic Virus CDMO Services Market: Company Product Type Footprint
Table 16. Oncolytic Virus CDMO Services Market: Company Product Application Footprint
Table 17. Oncolytic Virus CDMO Services Mergers & Acquisitions Activity
Table 18. United States VS China Oncolytic Virus CDMO Services Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Oncolytic Virus CDMO Services Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Oncolytic Virus CDMO Services Revenue Market Share (2018-2023)
Table 23. China Based Oncolytic Virus CDMO Services Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Oncolytic Virus CDMO Services Revenue Market Share (2018-2023)
Table 26. Rest of World Based Oncolytic Virus CDMO Services Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Oncolytic Virus CDMO Services Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Oncolytic Virus CDMO Services Revenue Market Share (2018-2023)
Table 29. World Oncolytic Virus CDMO Services Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Oncolytic Virus CDMO Services Market Size by Type (2018-2023) & (USD Million)
Table 31. World Oncolytic Virus CDMO Services Market Size by Type (2024-2029) & (USD Million)
Table 32. World Oncolytic Virus CDMO Services Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Oncolytic Virus CDMO Services Market Size by Application (2018-2023) & (USD Million)
Table 34. World Oncolytic Virus CDMO Services Market Size by Application (2024-2029) & (USD Million)
Table 35. Recipharm (Vibalogics) Basic Information, Area Served and Competitors
Table 36. Recipharm (Vibalogics) Major Business
Table 37. Recipharm (Vibalogics) Oncolytic Virus CDMO Services Product and Services
Table 38. Recipharm (Vibalogics) Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Recipharm (Vibalogics) Recent Developments/Updates
Table 40. Recipharm (Vibalogics) Competitive Strengths & Weaknesses
Table 41. IDT Biologika Basic Information, Area Served and Competitors
Table 42. IDT Biologika Major Business
Table 43. IDT Biologika Oncolytic Virus CDMO Services Product and Services
Table 44. IDT Biologika Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. IDT Biologika Recent Developments/Updates
Table 46. IDT Biologika Competitive Strengths & Weaknesses
Table 47. FUJIFILM Diosynth Biotechnologies Basic Information, Area Served and Competitors
Table 48. FUJIFILM Diosynth Biotechnologies Major Business
Table 49. FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Product and Services
Table 50. FUJIFILM Diosynth Biotechnologies Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
Table 52. FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
Table 53. Exothera Basic Information, Area Served and Competitors
Table 54. Exothera Major Business
Table 55. Exothera Oncolytic Virus CDMO Services Product and Services
Table 56. Exothera Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Exothera Recent Developments/Updates
Table 58. Exothera Competitive Strengths & Weaknesses
Table 59. Lonza Basic Information, Area Served and Competitors
Table 60. Lonza Major Business
Table 61. Lonza Oncolytic Virus CDMO Services Product and Services
Table 62. Lonza Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Lonza Recent Developments/Updates
Table 64. Lonza Competitive Strengths & Weaknesses
Table 65. Creative Biolabs Basic Information, Area Served and Competitors
Table 66. Creative Biolabs Major Business
Table 67. Creative Biolabs Oncolytic Virus CDMO Services Product and Services
Table 68. Creative Biolabs Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Creative Biolabs Recent Developments/Updates
Table 70. Creative Biolabs Competitive Strengths & Weaknesses
Table 71. Takara Bio Basic Information, Area Served and Competitors
Table 72. Takara Bio Major Business
Table 73. Takara Bio Oncolytic Virus CDMO Services Product and Services
Table 74. Takara Bio Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Takara Bio Recent Developments/Updates
Table 76. Takara Bio Competitive Strengths & Weaknesses
Table 77. Libentech Basic Information, Area Served and Competitors
Table 78. Libentech Major Business
Table 79. Libentech Oncolytic Virus CDMO Services Product and Services
Table 80. Libentech Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Libentech Recent Developments/Updates
Table 82. Libentech Competitive Strengths & Weaknesses
Table 83. ABL Basic Information, Area Served and Competitors
Table 84. ABL Major Business
Table 85. ABL Oncolytic Virus CDMO Services Product and Services
Table 86. ABL Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. ABL Recent Developments/Updates
Table 88. ABL Competitive Strengths & Weaknesses
Table 89. Nabios Basic Information, Area Served and Competitors
Table 90. Nabios Major Business
Table 91. Nabios Oncolytic Virus CDMO Services Product and Services
Table 92. Nabios Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Nabios Recent Developments/Updates
Table 94. Nabios Competitive Strengths & Weaknesses
Table 95. Halix Basic Information, Area Served and Competitors
Table 96. Halix Major Business
Table 97. Halix Oncolytic Virus CDMO Services Product and Services
Table 98. Halix Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Halix Recent Developments/Updates
Table 100. Halix Competitive Strengths & Weaknesses
Table 101. Obio Technology Basic Information, Area Served and Competitors
Table 102. Obio Technology Major Business
Table 103. Obio Technology Oncolytic Virus CDMO Services Product and Services
Table 104. Obio Technology Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Obio Technology Recent Developments/Updates
Table 106. Obio Technology Competitive Strengths & Weaknesses
Table 107. Porton Advanced Basic Information, Area Served and Competitors
Table 108. Porton Advanced Major Business
Table 109. Porton Advanced Oncolytic Virus CDMO Services Product and Services
Table 110. Porton Advanced Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Porton Advanced Recent Developments/Updates
Table 112. Porton Advanced Competitive Strengths & Weaknesses
Table 113. WuXi ATU Basic Information, Area Served and Competitors
Table 114. WuXi ATU Major Business
Table 115. WuXi ATU Oncolytic Virus CDMO Services Product and Services
Table 116. WuXi ATU Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. WuXi ATU Recent Developments/Updates
Table 118. Genevoyager Basic Information, Area Served and Competitors
Table 119. Genevoyager Major Business
Table 120. Genevoyager Oncolytic Virus CDMO Services Product and Services
Table 121. Genevoyager Oncolytic Virus CDMO Services Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Oncolytic Virus CDMO Services Upstream (Raw Materials)
Table 123. Oncolytic Virus CDMO Services Typical Customers
LIST OF FIGURE
Figure 1. Oncolytic Virus CDMO Services Picture
Figure 2. World Oncolytic Virus CDMO Services Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Oncolytic Virus CDMO Services Total Market Size (2018-2029) & (USD Million)
Figure 4. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Oncolytic Virus CDMO Services Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Oncolytic Virus CDMO Services Revenue (2018-2029) & (USD Million)
Figure 13. Oncolytic Virus CDMO Services Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 16. World Oncolytic Virus CDMO Services Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 18. China Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 23. India Oncolytic Virus CDMO Services Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Oncolytic Virus CDMO Services by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oncolytic Virus CDMO Services Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oncolytic Virus CDMO Services Markets in 2022
Figure 27. United States VS China: Oncolytic Virus CDMO Services Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Oncolytic Virus CDMO Services Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Oncolytic Virus CDMO Services Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Oncolytic Virus CDMO Services Market Size Market Share by Type in 2022
Figure 31. Oncolytic Herpes Simplex Virus
Figure 32. Oncolytic Adenovirus
Figure 33. Oncolytic Vaccinia Virus
Figure 34. Others
Figure 35. World Oncolytic Virus CDMO Services Market Size Market Share by Type (2018-2029)
Figure 36. World Oncolytic Virus CDMO Services Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Oncolytic Virus CDMO Services Market Size Market Share by Application in 2022
Figure 38. R&D
Figure 39. Biopharmaceutical Manufacturers
Figure 40. Others
Figure 41. Oncolytic Virus CDMO Services Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
